share_log

Aimei Health Technology Co., Ltd Announces Pricing of $60 Million Initial Public Offering

Aimei Health Technology Co., Ltd Announces Pricing of $60 Million Initial Public Offering

愛美健康科技有限公司宣佈6000萬美元首次公開募股的定價
GlobeNewswire ·  2023/12/02 06:28

NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (NASDAQ: AFJKU, the "Company") announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit. The units are expected to be listed on The NASDAQ Global Market ("NASDAQ") and trade under the ticker symbol "AFJKU" beginning December 4, 2023. Each unit consists of one ordinary share and one right. Each right entitles the holder thereof to receive one-fifth (1/5) of one ordinary share upon the consummation of an initial business combination. No fractional rights will be issued upon separation of the units. As a result, 5 rights are needed to receive one ordinary share at the closing of the initial business combination. Once the securities comprising the units begin separate trading, the common stock and rights are expected to be listed on NASDAQ under the symbols "AFJK" and "AFJKR", respectively.

紐約,2023年12月1日(GLOBE NEWSWIRE)——艾美健康科技股份有限公司(納斯達克股票代碼:AFJKU,以下簡稱 “公司”)今天宣佈,其首次公開發行600萬套的定價爲每單位10美元。這些單位預計將於2023年12月4日起在納斯達克全球市場(“納斯達克”)上市,股票代碼爲 “AFJKU”。每個單位由一股普通股和一股權利組成。每項權利都使該權利的持有人有權在初始業務合併完成後獲得普通股的五分之一(1/5)。單位分離後將不發放任何部分權利。因此,在初始業務合併結束時,需要5股權利才能獲得一股普通股。一旦構成這些單位的證券開始單獨交易,普通股和股票預計將分別在納斯達克上市,股票代碼爲 “AFJK” 和 “AFJKR”。

The underwriters have been granted a 45-day option to purchase up to an additional 900,000 units offered by the Company to cover over-allotments, if any.

承銷商已獲得45天的選擇權,可以額外購買公司提供的最多90萬套單位,以彌補超額配股(如果有)。

The offering is expected to close on December 6, 2023, subject to customary closing conditions.

此次發行預計將於2023年12月6日結束,但須遵守慣例成交條件。

Spartan Capital Securities, LLC acted as sole book running manager in the offering. Loeb & Loeb LLP is serving as legal counsel to the Company. Hunter, Taubman Fischer & Li LLC is serving as legal counsel to Spartan Capital Securities, LLC.

斯巴達資本證券有限責任公司擔任本次發行的唯一賬面經理。Loeb & Loeb Llp擔任該公司的法律顧問。Hunter、Taubman Fischer & Li LLC擔任斯巴達資本證券有限責任公司的法律顧問。

ARC Group Limited acted as financial advisor to the Company.

ARC集團有限公司擔任該公司的財務顧問。

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 30, 2023. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Spartan Capital Securities, LLC, 45 Broadway, 19th Floor, New York, NY 10006. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.

美國證券交易委員會於2023年11月30日宣佈與這些證券有關的註冊聲明生效。此次發行僅通過招股說明書進行,招股說明書的副本可通過聯繫位於紐約州紐約百老匯45號19樓的斯巴達資本證券有限責任公司獲取。註冊聲明的副本可以通過美國證券交易委員會的網站www.sec.gov獲取。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新聞稿不構成出售要約或招攬買入要約,在根據任何此類州或司法管轄區的證券法進行註冊或資格認證之前,此類要約、招標或出售是非法的州或司法管轄區也不得出售這些證券。

About Aimei Health Technology Co., Ltd

關於愛美健康科技股份有限公司

Aimei Health Technology Co., Ltd is a blank check company newly incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although it is the Company's intention to pursue prospective targets that are focused on healthcare innovation.

Aimei Health Technology Co., Ltd是一家作爲開曼群島豁免公司新成立的空白支票公司,其目的是與一個或多個企業或實體進行合併、股份交換、資產收購、股份購買、資本重組、重組或類似的業務合併。儘管公司打算追求專注於醫療創新的潛在目標,但公司確定潛在目標業務的努力將不僅限於特定的行業或地理區域。

Forward-Looking Statements

前瞻性陳述

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

本新聞稿包括涉及風險和不確定性的前瞻性陳述。前瞻性陳述是非歷史事實的陳述。此類前瞻性陳述存在風險和不確定性,這可能導致實際結果與前瞻性陳述不同。公司明確聲明不承擔任何義務或承諾公開發布此處包含的任何前瞻性陳述的任何更新或修訂,以反映公司對其預期的任何變化或任何陳述所依據的事件、條件或情況的任何變化。

Contact:
Juan Fernandez Pascual
Aimei Health Technology Co., Ltd
10 East 53rd Street, Suite 3001
New York, NY 10022

聯繫人:
胡安·費爾南德斯·帕斯夸爾
愛美健康科技股份有限公司
東 53 街 10 號,套房 3001
紐約州紐約 10022


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論